KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $488.9 million.

  • Idexx Laboratories' Accumulated Expenses fell 434.23% to $488.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $488.9 million, marking a year-over-year decrease of 434.23%. This contributed to the annual value of $502.1 million for FY2024, which is 488.96% up from last year.
  • Idexx Laboratories' Accumulated Expenses amounted to $488.9 million in Q3 2025, which was down 434.23% from $417.0 million recorded in Q2 2025.
  • Idexx Laboratories' 5-year Accumulated Expenses high stood at $541.1 million for Q2 2024, and its period low was $366.9 million during Q1 2021.
  • Over the past 5 years, Idexx Laboratories' median Accumulated Expenses value was $431.0 million (recorded in 2021), while the average stood at $442.9 million.
  • As far as peak fluctuations go, Idexx Laboratories' Accumulated Expenses surged by 4842.56% in 2021, and later tumbled by 2294.24% in 2025.
  • Idexx Laboratories' Accumulated Expenses (Quarter) stood at $458.9 million in 2021, then decreased by 5.5% to $433.7 million in 2022, then grew by 10.39% to $478.7 million in 2023, then rose by 4.89% to $502.1 million in 2024, then decreased by 2.64% to $488.9 million in 2025.
  • Its Accumulated Expenses was $488.9 million in Q3 2025, compared to $417.0 million in Q2 2025 and $490.7 million in Q1 2025.